Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
The Boston drugmaker (Nasdaq: VRTX) says it put more than two decades of work into developing and bringing the new medicine to market. Stuart Arbuckle, Vertex’s chief operating officer ...